Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 219

1.

Targeting EMT in cancer: opportunities for pharmacological intervention.

Davis FM, Stewart TA, Thompson EW, Monteith GR.

Trends Pharmacol Sci. 2014 Jul 16. pii: S0165-6147(14)00109-6. doi: 10.1016/j.tips.2014.06.006. [Epub ahead of print] Review.

PMID:
25042456
[PubMed - as supplied by publisher]
2.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

PMID:
24886434
[PubMed - in process]
Free PMC Article
3.

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Front Oncol. 2014 Apr 9;4:75. doi: 10.3389/fonc.2014.00075. eCollection 2014.

PMID:
24782986
[PubMed]
Free PMC Article
4.

Mammographic density-a review on the current understanding of its association with breast cancer.

Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, Thompson EW.

Breast Cancer Res Treat. 2014 Apr;144(3):479-502. doi: 10.1007/s10549-014-2901-2. Epub 2014 Mar 11.

PMID:
24615497
[PubMed - in process]
5.

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.

Fifis T, Nguyen L, Malcontenti-Wilson C, Chan LS, Nunes Costa PL, Daruwalla J, Nikfarjam M, Muralidharan V, Waltham M, Thompson EW, Christophi C.

Cancer Med. 2013 Oct;2(5):595-610. doi: 10.1002/cam4.109. Epub 2013 Aug 18.

PMID:
24403226
[PubMed - in process]
Free PMC Article
6.

Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.

Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NP, Pinto C, Soo ET, van Denderen BJ, Hill P, Ramsay RG, Sarcevic B, Newgreen DF, Thompson EW.

Breast Cancer Res. 2013 Nov 27;15(6):R113. doi: 10.1186/bcr3580.

PMID:
24283570
[PubMed - in process]
Free PMC Article
7.

Assessment of gene expression of intracellular calcium channels, pumps and exchangers with epidermal growth factor-induced epithelial-mesenchymal transition in a breast cancer cell line.

Davis FM, Parsonage MT, Cabot PJ, Parat MO, Thompson EW, Roberts-Thomson SJ, Monteith GR.

Cancer Cell Int. 2013 Jul 29;13(1):76. doi: 10.1186/1475-2867-13-76.

PMID:
23890218
[PubMed]
Free PMC Article
8.

Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time.

Chew GL, Huang D, Huo CW, Blick T, Hill P, Cawson J, Frazer H, Southey MD, Hopper JL, Henderson MA, Haviv I, Thompson EW.

Breast Cancer Res Treat. 2013 Jul;140(2):285-97. doi: 10.1007/s10549-013-2642-7. Epub 2013 Jul 24.

PMID:
23881524
[PubMed - indexed for MEDLINE]
9.

Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance.

Pinto CA, Widodo E, Waltham M, Thompson EW.

Cancer Lett. 2013 Nov 28;341(1):56-62. doi: 10.1016/j.canlet.2013.06.003. Epub 2013 Jul 2. Review.

PMID:
23830804
[PubMed - indexed for MEDLINE]
10.

Progress in epithelial-mesenchymal transition research.

Newgreen DF, Thompson EW.

Cells Tissues Organs. 2013;197(6):421-3. doi: 10.1159/000351732. Epub 2013 Jun 14. No abstract available.

PMID:
23774311
[PubMed - indexed for MEDLINE]
Free Article
11.

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.

Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G, Thompson EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, Garber JE, Nikolsky Y, Blum JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K.

Cell Stem Cell. 2013 Jul 3;13(1):117-30. doi: 10.1016/j.stem.2013.05.004. Epub 2013 Jun 13.

PMID:
23770079
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent.

Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson SJ, Monteith GR.

Oncogene. 2014 May 1;33(18):2307-16. doi: 10.1038/onc.2013.187. Epub 2013 May 20.

PMID:
23686305
[PubMed - indexed for MEDLINE]
13.

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Mol Cancer. 2013 Mar 27;12:24. doi: 10.1186/1476-4598-12-24.

PMID:
23537295
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Determining epithelial contribution to in vivo mesenchymal tumour expression signature using species-specific microarray profiling analysis of xenografts.

Purdom E, Restall C, Busuttil RA, Schluter H, Boussioutas A, Thompson EW, Anderson RL, Speed TP, Haviv I.

Genet Res (Camb). 2013 Feb;95(1):14-29. doi: 10.1017/S0016672313000013. Epub 2013 Mar 18.

PMID:
23497823
[PubMed - indexed for MEDLINE]
15.

Cancer: The to and fro of tumour spread.

van Denderen BJ, Thompson EW.

Nature. 2013 Jan 24;493(7433):487-8. doi: 10.1038/493487a. No abstract available.

PMID:
23344357
[PubMed - indexed for MEDLINE]
16.

An adipoinductive role of inflammation in adipose tissue engineering: key factors in the early development of engineered soft tissues.

Lilja HE, Morrison WA, Han XL, Palmer J, Taylor C, Tee R, Möller A, Thompson EW, Abberton KM.

Stem Cells Dev. 2013 May 15;22(10):1602-13. doi: 10.1089/scd.2012.0451. Epub 2013 Jan 29.

PMID:
23231040
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N.

PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.

PMID:
23056490
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A.

EMBO Mol Med. 2012 Aug;4(8):675-84. doi: 10.1002/emmm.201101131. Epub 2012 Jun 25. Review.

PMID:
22733553
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers.

Chew GL, Huang D, Lin SJ, Huo C, Blick T, Henderson MA, Hill P, Cawson J, Morrison WA, Campbell IG, Hopper JL, Southey MC, Haviv I, Thompson EW.

Breast Cancer Res Treat. 2012 Aug;135(1):177-87. doi: 10.1007/s10549-012-2128-z. Epub 2012 Jun 23.

PMID:
22729891
[PubMed - indexed for MEDLINE]
20.

Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer.

Gunasinghe NP, Wells A, Thompson EW, Hugo HJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):469-78. doi: 10.1007/s10555-012-9377-5. Review.

PMID:
22729277
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk